Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Congestive Heart Failure
Intervention: Candesartan (Drug); Placebo (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Chris Granger, MD, Principal Investigator
Summary
A study to evaluate the effect of Atacand on patients with heart failure with depressed left
ventricular function
Clinical Details
Official title: Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function
Study design: Treatment, Randomized, Double-Blind, Parallel Assignment, Efficacy Study
Primary outcome: Cardiovascular mortality or hospitalisation due to congestive heart failure
Secondary outcome: Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male or female aged 18 or above
- Congestive Heart Failure with symptoms for more than 4 weeks before starting study
- Provision of informed consent
Exclusion Criteria:
- Current low blood pressure with symptoms
- Liver disease considered significant by the study doctor
- Pregnant or lactating females
Locations and Contacts
Additional Information
Starting date: March 1999
Ending date: June 2003
Last updated: March 12, 2008
|
